he re- commercialization of Iclusig with a narrower label, and we consider the REMS accompanied by four PMRs without an Elements to Assure Safe Use (ETASU) to be a favorable. We discuss the new label, REMS, and PMRs in detail herein. We are upgrading Ariad shares to Outperform and increasing our price